About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline

71 Tul. L. Rev. 1211 (1996-1997)
Commercialization of Genetic Testing Services: The FDA, Market Forces, and Biological Tarot Cards

handle is hein.journals/tulr71 and id is 1231 raw text is: Commercialization of Genetic Testing
Services: The FDA, Market Forces, and
Biological Tarot Cards
Michael J. Malinowski
Robin J.R. Blatt*
Many women fear being diagnosed with breast cancer, and rightfully so. Despite the
capabilities of modern medicine, the cumulative lifetime risk of getting the disease has risen to
one in eight and, despite decades of research, no cures exist. In this Article, the authors explore
the commercialization of so-called breast cancer gene tests, based upon genetic alterations
linked to the disease. Although the authorsfully address this specific technology, they use what
constitutes the seminal case of predictive genetic testing to analyze the adequacy of the existing
regulatory framework The authors conclude that the present regulatory system is inadequate
and places a dangerous amount of reliance on primary care physicians. Their conclusion is
grounded in the observation that most primary care physicians lack sufficient knowledge about
this evolving investigative technology-which is highly subject to misinterpretation, and,
though potentially helpful to some high risk patients, offers questionable clinical value for
the general public. The authors set forth numerous proposals to promote both the quality and
clinical value of predictive genetic testing so that it conforms to public health standards and
can be properly integrated as a reliable component of medical care in specific situations.
I.    INTRODUCMION .......................................................................... 1212
II.   TODAY'S TECHNOLOGY, YESTERDAY'S REGULATIONS ............ 1220
A.    Overview of Genetic Testing Capabilities ....................... 1222
B.    Existing Regulations ........................................................ 1229
©     Copyright 1997 TuLANE LAw REviEw; Michael J. Malinowski, J.D.; and Robin
J.R. Blatt, M.P.H., R.N., Coordinator, Massachusetts Genetics Program, Department of
Public Health.
*     The authors are members of the faculty of the Eunice Kennedy Shriver Center
for Mental Retardation. The opinions expressed are solely the authors' unless attributed to
others and are in no way attributable to any of the institutions with which they are affiliated.
Appreciation is due to the law firm of Kirkpatrick & Lockhart LLP for supporting this
project and to our colleagues for their helpful suggestions and other contributions, including
Maureen O'Rourke and members of the Massachusetts Legislature's Special Committee on
Genetic Information Policy. Our special appreciation to Jan Platner, J.D., Executive
Director of the Massachusetts Breast Cancer Coalition, and the others who shared their
professional and personal experiences with the issues addressed in this Article. We also
thank Patricia Murphy, M.D. with OncorMed, Inc., and Brian Murphy, Ph.D. with Myriad
Genetic Laboratories, Inc., for reviewing an earlier version of this Article and sharing their
vast practical knowledge. In addition, we acknowledge the contribution of Terenia Guill and
Jana Grauberger and their colleagues at the TULANE LAW REVIEW.
1211

What Is HeinOnline?

HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Short-term subscription options include 24 hours, 48 hours, or 1 week to HeinOnline.

Contact us for annual subscription options:

Already a HeinOnline Subscriber?

profiles profiles most